Stockscreener 앱 받기
211.36
1.11%
2.331
전일 마감가:
$209.03
열려 있는:
$209.98
하루 거래량:
2.73M
Relative Volume:
0.50
시가총액:
$372.17B
수익:
$56.33B
순이익/손실:
$4.28B
주가수익비율:
88.07
EPS:
2.4
순현금흐름:
$17.83B
1주 성능:
+3.57%
1개월 성능:
+11.16%
6개월 성능:
+6.91%
1년 성능:
+18.14%
1일 변동 폭
$208.91
$212.09
1주일 범위
$201.43
$212.09
52주 변동 폭
$153.58
$212.09
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
211.40 | 372.17B | 56.33B | 4.28B | 17.83B | 2.40 |
|
LLY
Lilly Eli Co
|
932.59 | 876.70B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
90.30 | 398.98B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
166.59 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
92.37 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie Enters Obesity Market With Up to $2.2 Billion Gubra Deal - BNN Bloomberg
Top Monthly Winners: AbbVie, Philip Morris, and More - Baystreet.ca
AbbVie and Gubra Partner to Develop GUB014295 for the Treatment of Obesity - Contract Pharma
AbbVie enters obesity drug market with Danish drugmaker - Crain's Chicago Business
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug - Yahoo Finance
AbbVie Reaches Analyst Target Price - Nasdaq
AbbVie enters obesity drug market with up to $2.2 billion Gubra deal - Business Standard
AbbVie enters obesity space with $2.3bn Gubra deal - Pharmaceutical Technology
AbbVie steps into the obesity drug race, licensing medicine from Danish firm - STAT
Gubra soars 23% on on AbbVie obesity drug licensing deal By Investing.com - Investing.com Canada
AbbVie pays Gubra $350m upfront to enter obesity field - pharmaphorum
AbbVie Enters License Deal With Gubra to Develop Obesity Treatment -March 03, 2025 at 04:01 am EST - Marketscreener.com
Gubra surges on AbbVie partnership for obesity treatment - TradingView
AbbVie, Gubra Sign License Deal to Develop Amylin Analog for Obesity Treatment -March 03, 2025 at 02:12 am EST - Marketscreener.com
AbbVie and Gubra Announces License Agreement to Develop an Amylin Analog for the Treatment of Obesity - Marketscreener.com
Pancreatic Cancer Market: Report Analysis and Research Studies | AbbVie, Amgen, Genentech - openPR
AbbVie Inc. (ABBV): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
AbbVie Inc. (NYSE:ABBV) SVP Sells $3,853,399.04 in Stock - MarketBeat
US Bancorp DE Sells 24,245 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Mutual of America Capital Management LLC - MarketBeat
SVB Wealth LLC Invests $45.76 Million in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Bought by Illinois Municipal Retirement Fund - MarketBeat
Lake Street Advisors Group LLC Grows Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Longbow Finance SA Has $6.98 Million Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie (NYSE:ABBV) Shares Up 0.4%Still a Buy? - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Nelson Capital Management LLC - MarketBeat
DMKC Advisory Services LLC Buys Shares of 1,335 AbbVie Inc. (NYSE:ABBV) - MarketBeat
Exchange Capital Management Inc. Purchases Shares of 1,587 AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie (NYSE:ABBV) Trading Up 0.3%Should You Buy? - MarketBeat
AbbVie Inc. (NYSE:ABBV) EVP Timothy J. Richmond Sells 29,917 Shares - MarketBeat
AbbVie Inc. (NYSE:ABBV) Stock Position Lifted by Trifecta Capital Advisors LLC - MarketBeat
AbbVie (NYSE:ABBV) Sets New 52-Week HighShould You Buy? - MarketBeat
AbbVie SVP Buckbee sells $3.85 million in stock - Investing.com India
AbbVie EVP Richmond sells $6.07 million in stock - Investing.com
Aldeyra Therapeutics, Inc. SEC 10-K Report - TradingView
Europe poised to OK another use for AbbVie's Rinvoq - Crain's Chicago Business
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector? - Nasdaq
AbbVie's Next Big Moneymaker? This Drug Just Took a Huge Step Toward Approval - Yahoo Finance
OPZELURA Continues to Revolutionize Dermatology Market with Strong Market Uptake | DelveInsight - GlobeNewswire Inc.
AbbVie stock soars to all-time high, reaching $207.34 - Investing.com
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA - Pharmaceutical Technology
AbbVie Stock: Is ABBV Outperforming The Healthcare Sector? - Barchart
AbbVie closes on Rinvoq approval in inflamed artery disease - pharmaphorum
AbbVie Inc. (NYSE:ABBV) Stock Holdings Decreased by Anchor Capital Advisors LLC - MarketBeat
AbbVie Gets CHMP Backing of Rinvoq in Giant Cell Arteritis - MarketWatch
Commonwealth Retirement Investments LLC Has $8.69 Million Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Pine Valley Investments Ltd Liability Co Raises Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
FourThought Financial Partners LLC Takes $3.20 Million Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Receives Positive Opinion on Giant Cell Arteritis Therapy From European Medicines Agency - Marketscreener.com
Y Intercept Hong Kong Ltd Acquires New Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
U.S. Acellular Dermal Matrices Market Projected To Witness Substantial Growth, 2025-2032: AbbVie Inc., Johnson - EIN News
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.30%
1.02%
자본화:
|
볼륨(24시간):